BRANMOOR
THURSDAY · 14 MAY 2026

Posaconazole

Injection · trading as Noxafil

To Be Discontinued Active (discontinuing) — Day 163 FDA record updated

High impact — Sole-source drug with no supply currently available from this manufacturer.

FDA shortage record

Substance
Posaconazole
Brand name
Noxafil
Manufacturers / suppliers
  • Merck Sharp & Dohme LLC
  • Merck Sharp & Dohme Corp.
2 known suppliers in current FDA data
Dosage form
Injection
Presentation
Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01)
Route(s)
INTRAVENOUS
Therapeutic category
Anti-Infective
Package NDC
0085-4331-01
Initially posted
12/02/2025
Days on shortage list
163
Discontinued
12/02/2025
Current FDA status
To Be Discontinued
Shortage entries (current dataset)
1 record for Posaconazole

Why this shortage matters

Anti-infective drugs — antibiotics, antivirals, and antifungals — treat bacterial, viral, and fungal infections. A shortage can delay care for serious hospital-acquired or opportunistic infections, where drug choice and timing directly affect patient outcomes.

FDA therapeutic class: Anti-Infective

Reason and context

Discontinuation of the manufacture of the drug

Manufacturer contact

Per the FDA record, the manufacturer's contact for supply inquiries is 800-672-6372.

If you're affected by this shortage

  • Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
  • Ask your pharmacy to check supply across multiple wholesalers and other branches.
  • Check current pharmacy pricing and availability via GoodRx (affiliate link).
  • Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.

Sources

Important

This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.